Company Description
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan, and India, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.
Company Background
With over 40 years of CDMO experience, Ajinomoto Bio-Pharma Services globally integrated network for large and small molecule development and manufacturing services. We have locations in Europe, North America, and Asia, providing the infrastructure and local support to meet your drug process development and manufacturing needs.
Services & Capabilities
Ajinomoto Bio-Pharma Services is your trusted manufacturing partner, providing a broad range of capabilities, regulatory excellence, and extensive experience, helping you navigate production challenges, provide solutions to your development process, and deliver your new therapies to patients who need it most.
Offering a broad range of manufacturing capabilities enables us to deliver the flexibility and guidance to meet different drug product needs from emerging therapeutics to life cycle management.
- Drug product fill finish
- Small molecule manufacturing
- Large molecule manufacturing
- Oligonucleotide and peptide synthesis
- ADC development and manufacturing
Our services are enhanced by a portfolio of innovative and advanced technologies that enable robust, scalable, cost- and time-efficient processes for large and small molecule manufacturing.
We have the capacity and know-how to manage projects from preclinical stage to commercialization successfully, but what truly differentiates us is our dedication to quality and our commitment to fostering trusted partnerships.